Electra Therapeutics Raises $350M in Offering
Summary
Electra Therapeutics expects gross proceeds of approximately $350 million from its offering. The company priced its IPO at $15.00 per share, offering 23,333,334 shares for $350.0 million gross proceeds, with a 30-day underwriters' option for 3,500,000 additional shares. Net proceeds are estimated at $319.9 million, and shares list on Nasdaq as ETRA. The offering is expected to close on September 21. This capital raise is significant for a life sciences company and will likely fund clinical development or operations. Investors will watch for details on use of proceeds and any dilution impact.
Updated with an SEC 424B4 filing · What changed
Updates
· SEC 424B4 — Electra priced its IPO at $15.00 per share, offering 23,333,334 shares for $350.0 million gross proceeds, with a 30-day underwriters' option for 3,500,000 additional shares. Net proceeds are estimated at $319.9 million, and shares list on Nasdaq as ETRA.
This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.